Answers are grounded in this paper and cite their sources.
Cross-sectional study assesses erythroferrone's link to mortality and iron levels in chronic kidney disease, suggesting implications for treatment.
Background and hypothesis The role of erythroferrone, a hormone synthesized in erythroid cells which suppresses hepatic production of hepcidin to increase systemic iron availability during erythropoiesis expansion, has not been sufficiently characterized in chronic kidney disease (CKD). Therefore, we evaluated its determinants and its association with mortality risk in patients with CKD stages 3–5. Methods In this cross-sectional study with longitudinal follow-up, erythroferrone, hepcidin, ferritin, transferrin saturation (TSAT), C-reactive protein, and nutritional status were assessed in 377 CKD patients (92 patients with CKD stage 3–4, 210 non-dialyzed patients with CKD stage 5, and 75 patients on peritoneal dialysis (PD)). Regression analyses were performed to investigate the association between erythroferrone and relevant variables. The association between erythroferrone and mortality risk was analyzed using Fine-Gray analysis, accounting for kidney transplantation as a competing risk. Results Erythroferrone, hepcidin, and ferritin were higher in PD patients and in CKD 5 patients, respectively, as compared to in CKD 3–4 patients, whereas the hepcidin-to-ferritin ratio did not differ between the cohorts. In linear regression analysis, erythroferrone was positively associated with the reticulocyte count, C-reactive protein, and CKD-severity, and negatively associated with TSAT and the hepcidin-to-ferritin ratio (and hepcidin), respectively. Further adjustment for erythropoiesis-stimulating agents (ESA) revealed that erythroferrone no longer showed an association with the severity of CKD or CRP-levels. Finally, erythroferrone was linked to both all-cause mortality and cardiovascular mortality. Conclusion Erythroferrone in CKD patients associated with the reticulocyte count and ESA dose and was inversely correlated with the hepcidin-to-ferritin ratio and TSAT, while its relationship with CKD stage may reflect ESA therapy. Higher circulating erythroferrone levels are associated with an increased mortality risk.
No takes yet. Share an insight, caveat, or question.
Pistis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: